Immunohematology Market to Reach USD 3.40 Billion by 2030 as Blood Safety, Transfusion Demand and Diagnostic Automation Advance

Immunohematology Market Overview and Market Estimation

The Immunohematology Market was valued at USD 2.58 Billion in 2023 and is projected to reach USD 3.40 Billion by 2030, expanding at a CAGR of 4% from 2024 to 2030. Immunohematology plays a critical role in transfusion medicine by examining interactions between red blood cell antigens and antibodies and supporting accurate blood typing, antibody screening and transfusion compatibility testing. Increasing investment by public and private organizations in blood banks is a key factor supporting market growth. The rising incidence of blood-related diseases, including blood cancers and sickle cell disease, is also increasing demand for blood transfusion procedures and associated testing technologies. Growth in diagnostic laboratories, modernization of blood-bank infrastructure and the increasing adoption of automated testing systems are creating additional opportunities. Automation can reduce manual intervention, improve laboratory productivity and help standardize testing workflows. At the same time, growing awareness of transfusion safety is encouraging healthcare facilities to adopt advanced reagents, analyzers and software. However, the high cost of analyzers and reagents, together with a shortage of skilled professionals, can constrain adoption, particularly in developing healthcare systems. Opportunities are emerging through high-throughput analyzers, automated antibody identification, advanced reagent technologies, connectivity solutions and laboratory information integration.

* Gain Competitive Market Advantage: https://www.maximizemarketresearch.com/request-sample/33950/ 

U.S. Market Trends and Investment

The United States remains a major market for immunohematology because North America held the highest regional share in 2023, supported by advanced healthcare infrastructure, skilled personnel, diagnostic centers and blood banks. In 2025, the U.S. blood-management ecosystem continued to emphasize technology that improves transfusion safety, laboratory efficiency and blood-component management. Haemonetics reported continued investment in technologies designed to lower the overall cost of plasma collection while maintaining quality and safety, while its fiscal 2025 reporting also highlighted growth in hospital blood-management technologies. At the laboratory level, automation remained a major technology direction. Bio-Rad's immunohematology portfolio includes the IH-500 system, which provides continuous sample loading, automated antibody titration, reagent stability and connectivity tools. In 2025, Bio-Rad also participated in the International Society of Blood Transfusion congress, demonstrating the IH-500 NEXT system and highlighting solutions for antibody identification and immunohematology workflow optimization. These developments indicate continued U.S. demand for automated blood-bank testing and digitally connected transfusion diagnostics.

Immunohematology Market Segmentation

Based on Product, the Immunohematology Reagents segment is expected to dominate the market during the forecast period. Reagents are essential components of blood-bank testing and are extensively used for immunohematology procedures. Increasing utilization of reagents in blood banks, demand for customized testing solutions and the expanding use of immunohematology within diagnostic technologies are supporting the segment's leading position.

Immunohematology Market Key Players
1.Bio-Rad Laboratories, Inc.
2.Immucor
3.Grifols
4.BD (Becton Dickinson)
5.Hologic, Inc.
6.Siemens Healthcare GmbH
7.ThermoFisher
8.Abbott
9.Beckman Coulter, Inc.
10.Ortho Clinical Diagnostics
11.Roche Diagnostics Corporation
12.Merck KGaA
13.Cardinal Health Inc.
14.CSL Ltd.
15.Danaher Corp.
16.MTC Invitro Diagnostics AG
17.F. Hoffmann-La Roche Ltd.
18.Antisel

Competitive Analysis

The MMR report identifies Bio-Rad Laboratories, Inc., Immucor, Grifols, BD (Becton Dickinson), and Hologic, Inc. among the key companies in the global Immunohematology Market. The accessible MMR report does not provide individual percentage market shares for these companies; therefore, unsupported market-share rankings have not been assigned.

Bio-Rad Laboratories: Bio-Rad continues to invest in automated immunohematology testing. Its IH-500 platform uses automation, continuous loading, automated antibody titration and data-management connectivity. The IH-500 NEXT further emphasizes reduced hands-on time, faster results and compact laboratory deployment.

Immucor: Immucor remains a major participant in transfusion diagnostics, providing blood-typing, antibody-screening and compatibility-testing solutions. Continued development of automated immunohematology workflows and reagent technologies can help laboratories improve accuracy and throughput while addressing workforce constraints.

Grifols: Grifols has an established blood-typing and immunohematology portfolio. Its Erytra Eflexis analyzer uses DG Gel technology for pre-transfusion compatibility testing, illustrating the industry's movement toward automated and standardized blood-bank workflows.

BD (Becton Dickinson): BD's broad blood-management and diagnostic capabilities position it to benefit from demand for safer transfusion processes and laboratory automation. Integration of connected diagnostics, workflow optimization and advanced sample-management technologies can support efficiency across blood-bank operations.

Hologic: Hologic's diagnostic technology portfolio and laboratory presence provide opportunities to participate in the broader movement toward automated and high-quality diagnostic testing. Continued investment in laboratory technologies and data connectivity can complement the increasing need for efficient blood-testing workflows.

Regional Analysis

United States: The U.S. is the leading country market within North America's dominant regional position. Advanced healthcare infrastructure, sophisticated blood banks, diagnostic laboratories and skilled professionals support adoption of immunohematology technologies. Automation and connectivity are increasingly important as laboratories seek higher productivity and consistent testing.

UK: The UK benefits from an established transfusion infrastructure and strong emphasis on blood safety. Increasing laboratory automation and demand for standardized testing provide opportunities for immunohematology reagent and analyzer suppliers.

Germany: Germany's advanced healthcare and diagnostic infrastructure supports adoption of sophisticated blood-testing technologies. Automated laboratory workflows can improve productivity and consistency across transfusion services.

France: France has an established healthcare system and transfusion infrastructure, creating demand for reliable blood typing, antibody screening and compatibility-testing solutions.

Japan: Japan's advanced healthcare technology ecosystem and aging population support continued investment in efficient diagnostic and transfusion technologies. Automation can help laboratories manage testing workloads while maintaining high quality standards.

China: China offers long-term growth opportunities through expanding healthcare infrastructure, increasing diagnostic capacity and continued development of blood-bank services. Growth in transfusion activity and modernization of laboratories can support demand for immunohematology reagents and automated analyzers.

Related Reports: 

Anti-Wrinkle Products Market https://www.maximizemarketresearch.com/market-report/anti-wrinkle-products-market/228942/ 

Personalized LASIK Surgery Market https://www.maximizemarketresearch.com/market-report/personalized-lasik-surgery-market/230753/ 

Venous Stents Market https://www.maximizemarketresearch.com/market-report/venous-stents-market/231857/ 

Conclusion

The Immunohematology Market is positioned for steady growth as healthcare systems place greater emphasis on blood safety, accurate transfusion compatibility, laboratory automation and advanced diagnostic technologies. Reagents will remain fundamental to market expansion, while automated analyzers, antibody-identification systems, digital connectivity and high-throughput testing can create new growth opportunities. Increasing investment in blood banks and the rising burden of blood-related diseases will continue to stimulate demand. In the longer term, manufacturers that combine reliable reagents with automation, software connectivity and efficient laboratory workflows are likely to gain a competitive advantage. The integration of immunohematology with broader digital laboratory systems represents a particularly important opportunity for improving testing efficiency, reducing manual errors and strengthening transfusion safety worldwide.

About Maximize Market Research

Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting firm known for delivering accurate, actionable, and data-driven insights. Our expertise spans diverse industries — including medical devices, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. We provide services such as market-validated forecasts, competitive intelligence, strategic consulting, and industry impact analysis, helping businesses navigate market complexities and achieve sustainable growth.

Contact Maximize Market Research

MAXIMIZE MARKET RESEARCH PVT. LTD.
2nd Floor, Naval IT Park Phase 3,
Pune-Bangalore Highway, Narhe,
Pune, Maharashtra 411041, India.
📞 +91 9607365656
📧 sales@maximizemarketresearch.com